New drug aims to tame Chemo-Related pancreatitis in kids
NCT ID NCT04195347
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study tests a drug called CM4620 in children and young adults who develop pancreatitis (inflammation of the pancreas) after receiving a chemotherapy drug called asparaginase. The goal is to see if CM4620 is safe and can reduce the severity of pancreatitis, preventing serious complications like fluid collections or tissue death. About 42 participants will be enrolled at St. Jude Children's Research Hospital.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PANCREATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novant Health Presbyterian Hemby Children's Hospital
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.